Loading
BCG033 is an experimental drug designed to carry chemotherapy to cancer cells. Its published evidence is from laboratory and animal studies.
AACR 2024 abstract 2616 describes BCG033 targeting PTK7 and TROP2. A vcMMAE construct with DAR 4 was tested in breast and lung xenografts; a separate BLD1102 TOP1 inhibitor construct with DAR 8 was tested in colorectal xenografts. These are distinct constructs, not a demonstrated dual-payload ADC. The cited results are preclinical and do not establish patient benefit.
1.BCG033's antibody arm binds TROP2 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"BCG033" OR ABSTRACT:"BCG033") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BCG033, not a curated reading list.
Shares Bispecific ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/